CHARGED ALPHA
Stock Detail
JNJ Healthcare Latest YouTube: Q1 2026

Johnson & Johnson

Live stock metrics, chart context, a quarter-by-quarter YouTube archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Library coverage

Quarters tracked
1
YouTube quarters live
1
Latest video
Q1 2026
YouTube available
Yes
Current price
$234.18
-0.41 (-0.17%)
Trailing / Forward P/E
21.23x
Forward: 18.44x
Market cap / Volume
Volume:
Revenue / Earnings Growth
9.9%
Earnings: -52.9%
Margins
26.7% op
Gross: 68.0% · Net: 21.8%
Balance sheet
1.03x current
Debt / Equity: 60.5
52-week range / Beta
$146.12 - $251.71
Beta: 0.33
Analyst target
$251.08
Upside: 7.2%
Cash / shareholder return
3.42% FCF yield
Dividend yield: 2.22%

Company context

Industry: Drug Manufacturers - General
Country: United States
Employees:
Price to book: 6.92x
Return on equity:
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Price chart

Market context for JNJ

Competitive view

JNJ vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Johnson & Johnson
JNJ
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Merck & Co.
MRK
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
AbbVie Inc.
ABBV
YouTube
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
JNJ
$564.35B
Johnson & Johnson
MRK
$294.39B
Merck & Co.
ABBV
$368.57B
AbbVie Inc.
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
JNJ
21.2x
Johnson & Johnson
MRK
16.4x
Merck & Co.
ABBV
87.5x
AbbVie Inc.
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
JNJ
18.4x
Johnson & Johnson
MRK
12.2x
Merck & Co.
ABBV
12.9x
AbbVie Inc.
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
JNJ
9.9%
Johnson & Johnson
MRK
5.0%
Merck & Co.
ABBV
10.0%
AbbVie Inc.
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
JNJ
-52.9%
Johnson & Johnson
MRK
-19.3%
Merck & Co.
ABBV
8354.5%
AbbVie Inc.
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
JNJ
26.7%
Johnson & Johnson
MRK
32.8%
Merck & Co.
ABBV
34.1%
AbbVie Inc.
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
JNJ
68.0%
Johnson & Johnson
MRK
77.2%
Merck & Co.
ABBV
71.6%
AbbVie Inc.
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
JNJ
21.8%
Johnson & Johnson
MRK
28.1%
Merck & Co.
ABBV
6.9%
AbbVie Inc.
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
JNJ
Johnson & Johnson
MRK
36.9%
Merck & Co.
ABBV
6225.0%
AbbVie Inc.
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
JNJ
3.4%
Johnson & Johnson
MRK
4.0%
Merck & Co.
ABBV
5.0%
AbbVie Inc.
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
JNJ
60.50x
Johnson & Johnson
MRK
95.96x
Merck & Co.
ABBV
-2064.10x
AbbVie Inc.
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
JNJ
1.03x
Johnson & Johnson
MRK
1.54x
Merck & Co.
ABBV
0.67x
AbbVie Inc.
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
JNJ
0.33
Johnson & Johnson
MRK
0.28
Merck & Co.
ABBV
0.36
AbbVie Inc.
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
JNJ
2.2%
Johnson & Johnson
MRK
2.8%
Merck & Co.
ABBV
3.2%
AbbVie Inc.
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
JNJ
7.2%
Johnson & Johnson
MRK
9.0%
Merck & Co.
ABBV
19.5%
AbbVie Inc.

YouTube timeline

Quarterly archive for JNJ

Each row is one quarter. Only the YouTube link is shown here for now.

Q1 2026
Video live
Published youtube complete
Quarterly earnings-analysis entry for Johnson & Johnson. Use the YouTube link on the right to jump straight into that quarter's video when it is live.